RESEARCH ARTICLE

Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth

Wen-Lung Ma1,2,3 | Ning Chang2 | Yingchun Yu2 | Yu-Ting Su1,2 | Guan-Yu Chen2 | Wei-Chung Cheng2 | Yang-Chang Wu1,2,3 | Ching-Chia Li4,5,6 | Wei-Chun Chang2,3,7 | Juan-Cheng Yang1,8

1Graduate Institute of Biomedical Sciences, Center for Tumor Biology, Department of Pharmacology, Chinese Medicine Research Center, Drug Development Center, and Graduate Institute of Chinese Medicine, Graduate Institute of Integrated Medicine, School of Medicine, China Medical University, Taichung, Taiwan
2Department of Medical Research, Chinese Medicine Research and Development Center, and Department of Obstetrics & Gynecology, China Medical University Hospital, Taichung, Taiwan
3Department of Nursing, Department of Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
4Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
5Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
6Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
7Department of Obstetrics and Gynecology, Asia University Hospital, Taichung, Taiwan
8School of Chinese Medicine, China Medical University, Taichung, Taiwan

Correspondence
Juan-Cheng Yang and Wei-Chun Chang, 91 Xueshi Rd., North District, Taichung 40403, Taiwan.
Email: qq91130554@gmail.com and wei66@seed.net.tw

Funding information
This work was supported by Ministry of Sciences and Technology, Taiwan (107-2320-B-039-017-MY3; 108-2320-B-039-017; 109-2327-B-039-002; 108-2314-B-039-043-MY3; 108-2314-B-039-052; 109-2320-B-039-006; 108-2622-B-039-005-CC2; 108-2320-B-039-063; 108-2320-B-039-062; 106-2321-B-037-004; 109-2320-B-039-028; and 109-2320-B-039-063), National Health Research Institute, Taiwan (NHRI-EX109-10705BI), China Medical University/Hospital (DMR-108-079, CMU108-MF-33, CMU109-MF-26, DMR-109-084, DMR-110-231, and DMR-111-118), and Kaohsiung Medical University Hospital (KMUH105-5R46).

Abstract

Introduction: Gastric cancer (GCa) is a malignancy with few effective treatments. Ursolic acid (UA), a bioactive triterpenoid enriched in Hedyotis diffusa Willd, known to suppress GCa without identified target. CYP19A1 (cytochrome P450 family 19A1; also known as aromatase, Ar) was correlated to GCa prognosis. Relatedly, Ar silencers, which halt the expression of Ar exhibited anti-GCa effects in experimental models, are currently being investigated.

Method: The docking simulation score of UA was compared with Ar inhibitors, e.g., letrozole, exemestane, in Ar protein crystallization. Hedyotis diffusa Willd ethanol extract, UA, or 5-fluracil were applied onto AGS, SC-M1, MKN45 GCa cells for cancer inhibition tests. Immunoblot for measuring gene expressions upon drug treatments, or gene knockdown/overexpression. Treatments were also applied in a MKN45 implantation tumor model. A web-based GCa cohort for Ar expression association with prognosis was performed.

Result: The ethanol extracts of Hedyotis diffusa Willd, enrich with UA, exhibited cytotoxic activity against GCa cells. Molecular docking simulations with the 3D Ar structure revealed an excellent fitting score for UA. UA increase cytotoxic, and suppressed colony, in addition to its Ar silencing capacity.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Gastric cancer (GCa) is the fifth most commonly occurring cancer and ranks second in terms of cancer mobility among all cancers worldwide.1–3 The incidence of GCa varies worldwide,4,5 but the disease has a poor prognosis in general, with a 5-year survival rate of only 10% or less.6 Most GCa patients are diagnosed at an advanced stage and quickly relapse, that is, within 12 months, following surgery.6–8 Resection is the first-choice treatment modality, yet high recurrence rates still occur following resection.9 Meanwhile, although chemotherapy is often effective against early stage GCa, patients with advanced GCa still have a poor prognosis when treated with chemotherapy.4,6,5 Therefore, there is currently a high clinical demand for new adjuvant or neoadjuvant chemotherapies for GCa.10 Among the various available chemoagents, 5-fluorouracil (5-FU)-based chemotherapy drugs are considered as standard therapy.11 Therefore, with respect to new drug development, the therapeutic outcomes of 5-FU treatment often serve as the baseline for comparison in GCa patients.9 Aside from 5-FU treatments, studies have shown that 15% of GCa patients are HER2-positive,12,13 and these patients can be treated with a HER2 inhibitor as an alternative treatment once 5-FU treatment has failed. However, most of the patients for whom 5-FU has failed are HER2-negative patients (only 5% are HER2-positive),14 meaning there is a huge unmet medical need of additional treatments for such patients. One of the important obstacles for slowing progression of the development for GCa therapeutics is the lacking of theranostic marker.4,15

One previous study has shown that ~20% of GCa patients overly express CYP19A1 (cytochrome P450 family 19 subfamily A member 1; also known as aromatase, Ar).16 Because Ar acts, in terms of biochemical function, as a metabolic enzyme to convert testosterone into estradiol,17 aromatase inhibitors have been developed and implemented as treatments for estrogen receptor (ESR)-positive breast cancer patients.18 Unfortunately, the nonsteroidal Ar inhibitors (e.g., anastrozole and letrozole) exert little cytotoxic efficacy, whereas one steroidal Ar inhibitor, exemestane, has shown excellent cancer-suppressive effects in a preclinical GCa model.19,20 This discrepancy in the effects of various Ar inhibitors is due to the novel mechanisms of action of these drugs. For example, Yang et al.20 revealed that exemestane suppresses GCa cell growth by silencing Ar expression in GCa. Hedyotis diffusa Willd ethanol extract could be a functional food supplement.

Moreover, UA synergistically facilitated 5-FU, (a standard GCa treatment) regimen in vitro. Consistent with those results, adding estradiol did not reverse the cancer-suppressing effects of UA, which confirmed UA acts as an Ar silencer. Furthermore, UA exhibited tumor-suppressing index (TSI) score of 90% over a 6-week treatment term when used for single dosing in xenograft tumor model. In the clinical setting, Ar expression was found to be higher in GCa tumors than normal parental tissue from the TCGA (The Cancer Genome Atlas) cohort, while high Ar expression associated with poor prognosis. Together, the results indicate UA could be used to treat GCa by silencing Ar expression in GCa. Hedyotis diffusa Willd ethanol extract could be a functional food supplement.

**KEYWORDS**
Ar silencer, CYP19A1/aromatase, gastric cancer, Hedyotis diffusa Willd, ursolic acid

2 | MATERIALS AND METHODS

2.1 | Molecular docking for simulating UA in CYP19A1

To evaluate the interaction between small molecular inhibitors and CYP19A1, the molecular docking
simulations were performed using AutoDock 4.2 with the Lamarckian genetic algorithm. The structural information of human placental aromatase (also known as CYP19A1; PDB ID: 3S7S) was obtained from the RCSB Protein Data Bank (https://www.rcsb.org/). We selected the PDB structure that co-crystalizes with the breast cancer drug exemestane. For the calculation of binding energy, the co-crystalized ligands were removed. Furthermore, the polar hydrogens and Kallman united atom charges were added into CYP19A1 for calculating the docking mode by the AutoDock Tool 1.5.6 interfaces (ADT). To optimize the small molecular inhibitors for the docking by the ADT as well. A grid box with dimensions of $40 \times 40 \times 40$ Å grid points at a spacing of 0.375 Å calculated by the AutoGrid program was centered at the coordinates of $x = 86.57, y = 54.12$, and $z = 45.85$. All the parameters for the docking were set to default except that the maximum number of energy evaluation increase was set to 25,000,000 per run. The results were analyzed with cluster analysis, and the simulation models were shown using the BIOVIA Discovery Studio 4.5 Visualizer (Dassault Systèmes, BIOVIA Corp.).

### 2.2 Cell culture and reagents

The human gastric cancer cell lines AGS, SCM1, and MKN45 were purchased from the Food Industry Research and Development Institute in Hsinchu, Taiwan. AGS, SCM1, and MKN45 cells were cultured in RPMI 1640 medium (RPMI) (GIBCO) with 10% fetal calf serum and 1% penicillin/streptomycin (GIBCO). The cell lines were maintained at 37°C in a humidified atmosphere of 5% CO₂. E2 (β-estradiol: E2758), 5-FU (F6627), and ursoic acid (U6753) were purchased from Sigma-Aldrich. Stock solution of 5-FU (10 mM), ursoic acid (100 mM), and 17β-estradiol (10 mM) was prepared in DMSO and 99.5% ethanol. Aliquoting these stock solutions and frozen them at $-20°C$. CYP19A1 plasmid (Cat. # HG15323-UT) and its control (pCMV3 vector; Cat. # CV011) were purchased from Sino Biological. Plasmids were transformed to DH5α competent cells and amplified in LB medium containing ampicillin (100 μg/ml) overnight using a 37°C shaker with speed at 180 rpm. Then the bacteria were harvested and plasmids were purified using Invitrogen plasmid extraction and purification kit according to the procedure provided by the manufacture.

### 2.3 Transient transfection

2.5 × 10⁵ cells were seeded in 6-cm dish, and the transfection was performed next day. The transfection reagent is Lipofectamine 2000 (Invitrogen). The operations, respectively, according to manufacturer’s instructions (Invitrogen or Promega). 3 microgram plasmid mixed with 20 microliter of Lipofectamine 2000 in 0.5 ml of Opti-MEM reduced serum medium (Thermo Fisher). The DNA–lipofectamine mixture was incubated at room temperature for 15 min, then the mixture was added to the cells in a 6-cm dish containing 1 ml of RPMI medium without fetal bovine serum and 1% antibiotics. After 6 h of transfection, the transfection medium was replaced by growth medium. Transfected cells were subjected to colony formation assay, cytotoxic assay, and western blotting 48–72 h later.

### 2.4 Cytotoxic analysis and IC50 calculation

The WST-1 assay was used for assessing cell growth. Briefly, 2.5 × 10³ cells/well were seeded in 96-well plates with RPMI/10% fetal bovine serum (FBS) and were incubated for 24 h. The drugs were then added following previous work, and the cells were further incubated (single treatment: UA [20, 40, 60, 80, and 100 μM] and 5-FU [10 μM]). After 48 h of incubation, 1:10/v:v of WST-1 (Roche) solution was added for a further 60-min incubation period, after which the cell viability was measured through colorimetric detection with an ELISA plate reader (BECKMAN COULTER PARADIGM TM Detection Platform) at an absorbance of 450 nm to generate an optical density proportional to the relative abundance of live cells in the given wells. The values of 50% inhibitory concentration (IC50) for each drug were determined using CalcuSyn software (Biosoft).

### 2.5 Colony formation assay and standard cell number count

The method used for colony formation assay and standard cell number count was modified from a previous study. In brief, four sets of 500 cells/well were seeded in a 6-well plates with RPMI/10% FBS and incubated for 24 h. Then, the cells in each set were treated, respectively, with the investigated drugs (vehicle, 5-FU: 10 μM, UA) for 7 days. Next, 1000 μl of 4% formaldehyde solution was added to the fixed cells in each well, after which the mixture was incubated at room temperature for 1 h. Then, the cells were covered with crystal violet
stain. After 1 h, the crystal violet was washed from the 6-well plates, and the cell colonies were photographed. The cell numbers were then counted using ImageJ software.

2.6 Combination index analysis

The theory of linear and nonlinear regression analysis by Chou-Talalay method was used to evaluate the synergy (CI < 1), additive (CI = 1), and antagonism (CI > 1) of the combination drug treatment. The combination index (CI) is calculated using the following formula:

\[ CI = \frac{C_{A,X}}{IC_{X,A}} + \frac{C_{B,X}}{IC_{X,B}} \]

2.7 Total RNA isolation and CDNA synthesis

RNA was extracted from AGS, SCM1, and MKN45 cells as in a previous study. In each 100-mm dish, 1 × 10⁶ cells/well were seeded with RPMI in 10% FBS and were then incubated for 24 h. The cells were then treated with UA (5, 10, and 15 μM) and were incubated at 37°C for a further 48 h. Cells that had reached 80%–90% confluency in the 100-mm dishes were then lysed with 1 ml of Trizol (Invitrogen). Next, phenol/chloroform was added, and the RNA-rich layers were separated by centrifugation. With the addition of 2-propanol, soluble RNA was then precipitated. Next, the RNA was rinsed with 75% ethanol and dried at room temperature before being dissolved in RNase-free water. For first-strand cDNA synthesis, 5 μg of total RNA was used to perform reverse transcription PCR with the PrimeScript™ RT reagent kit (TAKARA Bio Inc.), while synthesized miRNA cDNA was produced using the Mir-X™ miRNA First-Strand synthesis Kit (Clontech). The synthesized cDNA and miRNA were produced following the manufacturers’ instructions.

2.8 Quantitative real-time PCR analysis

A real-time detection system (Bio-Rad Laboratories, Inc.) and the KAPA™ SYBR FAST One-Step qRT-PCR Kit (KAPABIOSYSTEMS) were used according to the manufacturers’ instructions. Relative gene expression was determined by normalizing the expression level of the target gene to the expression level of a housekeeping gene (actin). Threshold value (Ct) dynamics were used (2−ΔΔCt) for the quantitation of gene expression. The qRT-PCR primer sequences used were as follows: 5′-TCT GTG GAA ATC CTG CGT CTT-3′, reverse 5′-TCT GTG GAA ATC CTG CGT CTT-3′.

2.9 Western blot

Cells were lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM, NaCl, 5 mM EDTA, pH 8.0, 30 mM NaF, 1 mM Na3VO4, 40 mM β-glycerophosphate, 0.1 mM PMSF, protease inhibitors, 10% glycerol, and 1% Nonidet-P40). Forty micrograms of protein per lane was prepared in 10% SDS gel for electrophoresis, and then the proteins were transferred onto PVDF membranes. These membranes were stained with anti-actin (sc-47778, Santa Cruz) and anti-aromatase (anti-CYP19A1: sc-374176, Santa Cruz) at 4°C overnight. Proteins were visualized and quantified using ChemiDoc system (Bio-Rad Laboratories).

2.10 Animal model

Six-week-old male BALB/cAnN. Cg-Foxn1nu/CrlNarl mice (National Laboratory Animal Center) were raised under specific pathogen-free conditions (Laboratory Animal Center of China Medical University Hospital). The xenograft tumor model used was modified from that presented in a previous study. 1 × 10⁷ of MKN45 cells were subcutaneous (s.c.) injected into two sites on the lower back of each mouse. When the tumor volume reached 200 mm³, the mice were randomly assigned to three groups (placebo, 5-FU (5 mg/kg), and ursoolic acid (20 mg/kg)). The mice then received IP injections of the assigned treatment three times a week for a total of 4 weeks. The mice were then sacrificed, and the tumor volume and tumor weight of each tumor were measured. The sizes of the tumors were also measured at the same time. The mice were then sacrificed and the tumors were harvested. All the animal studies were performed under the supervision, guidelines, and approval of the China Medical University Animal Care and Use Committee (#CMOIAUC-2019-028).

2.11 Statistical analysis

Statistical analyses were performed using the Student’s t-test. All of the experiments were repeated at least three
times, and a \( p \) value <0.05 was considered to be statistically significant.

3  |  RESULT

3.1  |  UA is an aromatase silencer in GCa cells

In this study, virtual screening with molecular docking calculations was performed to predict the binding affinities between various compounds and aromatase (CYP19A1) in order to identify compounds from the Taiwan Database of Extracts and Compounds (TDEC) that could potentially bind to the active site of aromatase. We ranked the top 10 compounds and compared them with known Ar inhibitors, for example, exemestane and letrozole, and found that UA was among the best in terms of performance in the fitting simulation. It showed that UA exhibited a better binding energy (−9.82 kcal/mol) than exemestane (−9.5 kcal/mol) and letrozole (−7.36 kcal/mol) (Figure 1A).

The docking model showed that UA can successfully dock into the active site of aromatase, and that it then formed 16 hydrophobic alkyl–alkyl interactions with 9 amino acids, namely, Ile133 (4.28 Å, 4.39 Å, 4.77 Å, and 5.23 Å), Ala306 (3.26 Å), Val370 (3.92 Å and 5.00 Å), Leu372 (5.07 Å), Val373 (4.05 Å), Met374 (3.82 Å), Cys437 (4.14 Å, 4.02 Å, and 5.20 Å), Ala438 (3.22 Å), and Leu477 (4.71 Å and 5.46 Å). In addition, it also formed one hydrophobic pi–alkyl interaction with the amino acid Trp224 (4.79 Å) (Figure 1B).

Exemestane can also successfully dock into the active site of aromatase. It formed five hydrophobic alkyl–alkyl interactions with two amino acids, namely, Val370 (4.27 Å, 4.70 Å, 5.10 Å, and 5.10 Å) and Val373 (4.28 Å). In addition, it also formed three hydrophobic pi–alkyl interactions with three amino acids, Phe134 (5.32 Å), Phe221 (5.05 Å), and Trp224 (5.10 Å). Furthermore, it formed two electrostatic hydrogen bond interactions with two amino acids, Arg115 (2.38 Å) and Met374 (1.97 Å). Likewise, its major structure was docked into the location of the co-crystal exemestane binding space in the active site of aromatase (Figure 1C). On the other hand, the letrozole exhibited a poor docking model (Figure 1D) compared to UA and exemestane. All the interactive distances of all kinds of interactions in every docked compound are shown in parentheses.

In order to test whether UA exerts a GCa suppression effect, in vitro tests were performed. As shown in Figure 2A, UA treatments exhibited dose-dependent growth suppression activity on AGS, SC-M1, and MKN45 GCa cells (with IC50 < 40 μM). When measuring Ar mRNA expressions, we found that UA can silence Ar expression on GCa cells within 15 μM (Figure 2B). When we co-treated GCa cells with a low dose of 5-FU (10 μM) and UA, we found that a synergistic cytotoxic activity occurred on the GCa cells (Figure 2C). To determine whether the drug combination has a synergistic effect or an antagonistic effect, the combination index (CI) of 5-FU and UA was calculated using CompuSyn software and at Fα 0.5 (50% cell death). Therefore, the combined effect using cytotoxic data generated from the WST-1 assays. The 5-FU+UA co-treatment on AGS, SC-M1, and MKN45 cells, the CI value is between 0.70 and 0.77, indicating significant synergy of combination effect on the three cell lines. Moreover, as we replicated a similar design in measuring colony-forming activity, a consistent result was observed (Figure 2D). As shown in Figure 1, UA suppressed cell growth and silenced Ar expression in GCa cells. Considering that the conventional function of Ar is estradiol (E2) production, a physiological relevance E2 dosing (10 nM) was co-treated on GCa cells to observe the resulting cytotoxic activity of UA. As shown in Figure 3A, adding E2 did not reverse the colony suppression effect of UA with effective cytotoxic dosing (referencing to data in Figure 2A). In addition, E2 co-treatment of GCa cells with UA to observe their colony-forming activity showed similar results (Figure 3B). While treated UA on GCa cells, the Ar protein abundance was significantly downregulated (Figure 3C). In order to test if UA colony-suppressing effect through Ar silencing, the Ar cDNA was transfected in GCa cells (Figure 3D). It appears that restoration of Ar expression in AGS and SCM-1 cells could significantly reverse UA-mediated colony-suppressing effect (Figure 3E,F). However, due to failure to overexpress Ar in MKN45 cells, we exclude this cell line in this experiment.

The data shown in Figures 1–3 demonstrated the specificity of UA binding on Ar, which resulted in Ar silencing and GCa cell growth suppression.

3.2  |  Potential use of UA, a novel aromatase silencer, for GCA patients

Moreover, we compared the tumor suppression efficacy of 5-FU and UA (Figure 4A,B) and evaluated their systemic toxicity (Figure 4C) in MKN45 cells xenografted to create a GCa in vivo model. The 5-FU treatment using a therapy relevant dosing 5 mg/kg,31 where UA was treated in an toxicological acceptable dose 20 mg/kg.32 We found that UA exerted extraordinary efficacy (TSI = −90%) compared to 5-FU (TSI = −40%). The tumor weight and tumor weight/body weight (TW/BW) ratio were significantly reduced in the UA-treated mice compared to the placebo-treated mice and 5-FU-treated mice (Figure 4C). The body weight was comparable in...
In order to survey Ar expression in GCa patients, the TCGA (The Cancer Genome Atlas; https://www.cancer.gov/tcga) database was introduced to observe Ar expressions in a clinical setting. As shown in Figure 5A, the normal parental expression of Ar was lower than that of GCa tumor lesions. This result indicates potential...
targeting specificity by introducing UA to treat GCa patients. Furthermore, the expression of Ar in GCa tumor lesions is also a prognostic indicator (Figure 5B). These data indicate the potential effectiveness of using UA to silence Ar expression in GCa patients.

Because UA exerts an anti-GCa activity via Ar silencing, it could potentially increase the value of UA-containing natural products used as food supplements, such as Hedyotis diffusa Willd, a widely accepted ethnopharmacological natural product for cancer prevention in which UA has been identified as an effective ingredient. In this study, therefore, we tested whether Hedyotis diffusa Willd ethanol extract could inhibit the viability of GCa cells. In our unpublished data, the batch of crude extract from Hedyotis diffusa Willd produced for this report was ~4%. With the administration of Hedyotis diffusa Willd ethanol extract onto GCa cells, the cytotoxic efficacy of the extract was shown to be dose-dependent (Figure 6).

To sum up, the Ar silencing activity of UA might be applied for GCa therapeutics. In addition, Hedyotis diffusa Willd ethanol extract was demonstrated to have potential value for the development as a health-promoting functional food supplement for GCa patients.

4 | DISCUSSION

The results of the current study revealed that UA targets Ar in GCa cells. UA can suppress GCa cells by silencing their Ar expression, which is a prognostic gatekeeper of GCa. In addition, Hedyotis diffusa Willd could potentially be introduced as a health-promoting food supplement. An illustration summarizing the results of this study is presented in Figure 7. The results raise two major issues that should be discussed and are deserving of further study.
In this study, we found that UA, similar to exemestane, could suppress the cell growth of GCa cells and silence their Ar mRNA expression (Figure 2). A previous study demonstrated that silencing Ar with shRNA yielded results consistent with those of UA found in this study. That study performed both by Yang et al. and this work clearly demonstrated a possibility that silencing Ar, in addition of suppressing Ar activity, could suppress GCa growth. Furthermore, the molecular docking simulations performed in this study revealed that both exemestane and UA exhibited similar MOA in binding with Ar protein (Figure 1). Those data strongly suggested that binding with Ar, presumably on the Trp224 and Met374 of Ar, might turn off the nonenzymatic function of Ar, which could in turn suppress GCa cell growth.
growth. Theoretically, there are two potential mechanisms involved in the silencing of Ar activity by UA and exemestane. One would occur through off-target transcriptional activity suppression, which might not be directly linked to Ar binding. The other would occur through an unidentified negative feedback signaling through which UA or exemestane suppresses the transcriptional activation of Ar.

Regarding the first hypothesis, there have been several studies that support this possibility. For instance, a previous report claimed that GW4064 (farnesoid X receptor agonist) decreased Ar expression in endometriotic cells through ERRK1/2 activation. Another study showed that megestrol acetate inhibited Ar mRNA expression through nuclear C/EBPβ in an ischemic reperfusion injury rat model. Such transcriptional suppression on the Ar genome provides good examples indicating that small compounds silence Ar expression transcriptionally.

As for the second hypothesis, there have also been reported examples of such regulation. For example, one study showed that a COX selective inhibitor (sulfonamide) was surprisingly found to generate selective aromatase modulation activity, in which an aromatic ring was formed with two hydrogen bond acceptors and there was a hydrophobic function of Ar which suppressed Ar mRNA expression. In another study, methylseleninic acid was found to act as a suppressor of aromatase expression through the direct suppression of the Ar promoter of PI4- and PI-specific aromatase mRNA expression. Those are two examples of small compounds suppressing, whether directly on Ar or through an Ar promoter, Ar transcriptional activity.
In this study, we demonstrated that CYP19A1 might be a target for natural products containing ursolic acid, a derivative natural compound from *Hedyotis diffusa* Willd. It was previously reported that *Hedyotis diffusa* Willd, a well-known Chinese herbal medicine also known as Bai-Hua-She-She-Ca and as *Oldenlandia diffusa* (Willd), can be used to treat chronic inflammation caused by conditions such as metabolic syndrome, hepatitis, cancer-related disease.\(^4^2\) Notably, *Hedyotis diffusa* Willd has also been used for patients with gastric cancer, and the overall survival analysis showed that *Hedyotis diffusa* Willd improves the outcome of patients with gastric cancer.\(^4^3\) According to National Health Insurance Research Database statistics, *Hedyotis diffusa* Willd is the most commonly prescribed Chinese herbal medicine for patients with gastric cancer.\(^4^3\) Moreover, phytochemistry studies have revealed that various natural products from *Hedyotis diffusa* Willd, such as triterpenes, flavonoids, and anthraquinones, have been reported to have anticancer activities.\(^4^2\) In the current report, the ethanol extracts from *Hedyotis diffusa* Willd
Willd were found to be able to suppress GCa cell growth in a dose-dependent manner. As was noted in the results section, 4% UA was detected in the ethanol extracts of Hedyotis diffusa Willd. With regard to industrial application, UA can be easily concentrated for the manufacturing health-promoting products. In conclusion, the current study revealed that UA, the anticancer agent from Hedyotis diffusa Willd with no identified target, might bind to Ar and, consequently, silence Ar gene transcription and ablate GCa cell growth.

ACKNOWLEDGMENTS
The authors are grateful to the National Center for High Performance Computing for providing computer time and facilities. The authors also thank the Center for Resources, Research and Development of Kaohsiung Medical University for the ChemBio3D Ultra 11.0 technical support. Appreciation also to the Taiwan Database of Extracts and Compounds for the assistance of offering chemical and biological information of extracts and compounds.

AUTHOR CONTRIBUTIONS
Wen-Lung Ma and Ning Chang executed most of the experiments, and drafted the manuscript. Guan-Yu Chen and Wei-Chung Cheng are responsible for computational biology. Yang-Chang Wu is responsible for acquiring the nature product. Ching-Chia Li and Wei-Chun Chang advised the translational study and edited the manuscript. Wei-Chun Chang and Juan-Cheng Yang supervised the entire project, supported this study, and final approval of the manuscript.

CONFLICT OF INTEREST
None.

ETHICAL STATEMENT
This study was not human sample related, therefore, approval from an institutional review board or ethics committee can be waived.

DATA AVAILABILITY STATEMENT
All the data can be provided upon reasonable requests to corresponding author.

ORCID
Wen-Lung Ma https://orcid.org/0000-0002-5571-3302
Guan-Yu Chen https://orcid.org/0000-0002-2773-8748

REFERENCES
1. Gonzalez CA, Sala N, Rokkas T. Gastric cancer: epidemiologic aspects. Helicobacter. 2013;18(Suppl 1):34-38.
2. Bray F, Ferlay J, Soerjomataram I, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(2018):394-424.
3. Ferlay J, Colombet M, Soerjomataram I, et al. GLOBOCAN sources and methods. Int J Cancer. 2018;144(2019):1941-1953.
4. Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-133.
5. Quadri HS, Smaglo BG, Morales SJ, et al. Gastric adenocarcinoma: a multimodal approach. Front Surg. 2017;4:42.
6. Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635-1649.
7. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064.
8. Coburn N, Cosby R, Klein L, et al. Staging and surgical approaches in gastric cancer: a systematic review. Cancer Treat Rev. 2018;63:104-115.
9. Xu ZY, Tang JN, Xie HX, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 2015;11:284-294.
10. Charalampakis N, Economopoulou P, Kotsantis I. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7(1):123-133.
11. Roberto Persiani SR, Biondi A, et al. Combined modality treatment options for improving the outcome of locally advanced gastric cancer. Suppl Tumori. 2007;2:41-74.
12. Cetin B, Ozet A. HER2/neu as target in gastric adenocarcinoma. Translational Gastroenterology Hepatol. 2016;1:59.
13. Matsuoka T, Yashiro M. Recent advances in the HER2 targeted therapy of gastric cancer. World J Clinical Cases. 2015;3:42-51.
14. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738-746.
15. Yan HHN, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23:882-897 e11.
16. Kobayashi H, Yoshida S, Shirasawa N, Maeda K, Naito A. Expression and localization of aromatase in human gastric mucosa: immunohistochemical study using biopsy materials. Histochem Cell Biol. 2019;151:21-28.
17. Melby JC, Azar ST, Delaney M, Holbrook M, Grifﬁng GT, Johnston JO. 19-Nor-corticoestrogens in genetic hypertension. Effects of inhibitors of 11 beta, 18, 19-hydroxylation. J Steroid Biochem Mol Biol. 1993;45:13-18.
18. Wang Y, Li S, Zhu L, et al. Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1. Clin Transl Oncol. 2019;21:1026-1033.
19. Chang WC, Huang SF, Lee YM, et al. Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival. Oncotarget. 2017;8:692-704.
20. Yang JC, Chang N, Wu DC, et al. Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer. J Cell Mol Med. 2019;23:7417-7426.
21. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785-2791.
22. Ghosh D, Lo J, Morton D, et al. Novel aromatase inhibitors by structure-guided design. J Med Chem. 2012;55:8464-8476.
23. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model. 1999;17:57-61.
24. Chung WM, Ho YP, Chang WC, et al. Increase paclitaxel sensitivity to better suppress serous epithelial ovarian cancer via ablating androgen receptor/aryl hydrocarbon receptor-ABCg2 axis. Cancers. 2019;11.
25. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440-446.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
27. Chang WC, Wang HC, Cheng WC, et al. LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity. Endocr Relat Cancer. 2020;27:81-95.
28. Yadav SS, Li J, Stockert JA, et al. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. Oncotarget. 2016;7:76181-76196.
29. Chung WM, Chang WC, Chen L, et al. MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro. Stem Cell Res Ther. 2013;4:88.
30. Chen L, Ma WL, Cheng WC, et al. Targeting lipid droplet lysophosphatidylcholine for cisplatin chemotherapy. J Cell Mol Med. 2020;24:7187-7200.
31. Seidlitz T, Chen YT, Uhlemann H, et al. Mouse models of human gastric cancer subtypes with stomach-speciﬁc CreERT2-mediated pathway alterations. Gastroenterology 157. 2019;1599-1614 e2.
32. Chen Z, Liu Q, Zhu Z, et al. Ursolic acid protects against proliferation and inﬂammatory response in LPS-treated gastric tumour cell models and by inhibiting NLRP3 in ﬂammosome activation. Cancer Manag Res. 2020;12:8413-8424.
33. Damia G, D’Incalci M. Genetic instability inﬂuences drug response in cancer cells. Curr Drug Targets. 2010;11:1317-1324.
34. Yang YC, Wei MC, Chiu HF, Huang TC. Development and validation of a modiﬁed ultrasound-assisted extraction method and a HPLC method for the quantitative determination of two triterpenic acids in Hedyotis diffusa. Nat Prod Commun. 2013;8:1683-1686.
35. Lee HZ, Bau DT, Kuo CL, Tsai RY, Chang YC, Chang YH. Clarification of the phenotypic characteristics and anti-tumor activity of Hedyotis diffusa. Am J Chin Med. 2011;39:201-213.
36. Li Q, Wang X, Shen A, et al. Hedyotis diffusa Wild overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2. Exp Ther Med. 2015;10:1845-1850.
37. Gnoatto SC, Dassonville-Klimpt A, Da Nascimento S, et al. Evaluation of ursolic acid isolated from Ilex paraguariensis and derivatives on aromatase inhibition. Eur J Med Chem. 2008;43:1865-1877.
38. Wu PL, Zeng C, Zhou YF, Yin L, Yu XL, Xue Q. Farnesoid X receptor agonist GW46046 inhibits aromatase and ERbeta expression in human endometriotic stromal cells. Reprod Sci. 2019;26:1111-1120.
39. Kelicen Ugur P, Lule S, Cincioglu M, Pekiner C, Gursoy-ozdemir Y. Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBPbeta in reperfusion injury-induced ischemic rat hippocampus. Eur J Pharmacol. 2011;654:217-225.
40. Brueggemeier RW, Su B, Darby MV, Sugimoto Y. Selective regulation of aromatase expression for drug discovery. J Steroid Biochem Mol Biol. 2010;118:207-210.
41. Gao R, Zhao L, Liu X, et al. Methylselenenic acid is a novel suppressor of aromatase expression. J Endocrinol. 2012;212:199-205.
42. Chen R, He J, Tong X, Tang L, Liu M. The Hedyotis diffusa Wild. (Rubiaceae): a review on phytochemistry, pharmacology, quality control and pharmacokinetics. Molecules. 2016;21.
43. Hung KF, Hsu CP, Chiang JH, et al. Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: a nationwide retrospective matched-cohort study. J Ethnopharmacol. 2017;199:168-174.